Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation-Reference-Cited by-同舟云学术

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation

Published:2017-02-23 Issue:8 Volume:129 Page:970-980
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Harder Markus J.¹,Kuhn Nadine²,Schrezenmeier Hubert³⁴,Höchsmann Britta³⁴,von Zabern Inge³⁴,Weinstock Christof³⁴,Simmet Thomas¹,Ricklin Daniel⁴^ORCID,Lambris John D.⁵,Skerra Arne²,Anliker Markus³⁴,Schmidt Christoph Q.¹

Affiliation:

1. Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany;

2. Lehrstuhl für Biologische Chemie, Technische Universität München, Freising, Germany;

3. Institute of Transfusion Medicine, University of Ulm, Ulm, Germany;

4. Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service and University Hospital of Ulm, Ulm, Germany; and

5. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

Abstract

Key Points Strong complement activation overrides the terminal pathway inhibition by the anti-C5 antibody eculizumab. The more powerful complement is activated, the less effective is terminal pathway inhibition by diverse anti-C5 agents.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/8/970/1465735/blood732800.pdf

Reference58 articles.

1. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria;Hillmen;N Engl J Med,2006

2. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria;Brodsky;Blood,2008

3. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome;Legendre;N Engl J Med,2013

4. Paroxysmal nocturnal hemoglobinuria;Brodsky;Blood,2014

5. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015;Noris;Am J Kidney Dis,2015

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

2. The complement model disease paroxysmal nocturnal hemoglobinuria;European Journal of Immunology;2024-08-05

3. CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation;Blood Advances;2024-08-02

4. Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment;TRANSFUS MED HEMOTH;2024

5. A Cell-Based Assay to Measure the Activity of the Complement Convertases;Kidney International Reports;2024-07